Gilead Sciences, Inc. (NASDAQ:GILD) presented new long-term data reinforcing the safety and efficacy profile of Livdelzi (seladelpar) for primary biliary cholangitis (PBC) at The Liver Meeting hosted by the American Association for the Study of Liver Diseases in Washington, D.C. The biotech giant, with a market capitalization of $153.26 billion, has seen its shares climb 36.43% year-to-date, currently trading near its 52-week high of $124.61.
Real-world data from 396 patients showed Livdelzi’s effectiveness as an alternative for those switching from obeticholic acid and as a second-line therapy. Among the patients analyzed, 130 switched from obeticholic acid while 266 used Livdelzi as second-line or monotherapy. Reductions in alkaline phosphatase (ALP) were observed in both groups, with most patients achieving ALP levels below 1.67×ULN. Safety labs remained stable, and 93% of patients continued Livdelzi treatment throughout the observation period.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.